Core Viewpoint - The National Medical Products Administration (NMPA) of China has announced that foreign drugs approved for sale in China can be imported and marketed if they meet specific criteria, which may enhance the availability of essential medications in the market [1] Group 1: Approval Criteria - Approved foreign drugs must fall into one of the following categories: original or modified drugs [1] - Drugs listed in the National Shortage Drug List, National Key Monitoring List for Clinically Essential Drugs, Encouraged Generic Drug List, or Encouraged Research and Application List for Pediatric Drugs [1] - Drugs indicated for diseases included in the Rare Disease List [1] - Drugs that were temporarily imported under the Temporary Importation Work Plan for Clinically Urgent Drugs before being approved for sale in China [1] - Drugs that qualify for expedited registration procedures according to the Drug Registration Management Measures [1] - Other drugs as specified by the State Council's drug regulatory authority [1]

Core Viewpoint - Jiangsu Province has issued policies to promote deep reforms in drug and medical device regulation, aiming to enhance the high-quality development of the pharmaceutical industry [1] Group 1: Support for Innovation - The policies emphasize support for the research and development of innovative products, focusing on areas such as innovation, clinical needs, and rare disease treatments [1] - A series of provincial science and technology projects will be implemented to support the development of cutting-edge medical technologies, including cell and gene therapy drugs, foreign-approved drugs, radioactive drugs, medical robots, and brain-computer interface devices [1] Group 2: Enhancement of Testing and Monitoring Capabilities - The initiative includes advancing the construction of testing platforms in emerging fields such as brain-computer interfaces and artificial organs [1] - The goal is to create advantageous testing projects in the field of medical acoustics [1]